Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
BlackRock, Inc. filed an amended ownership report stating that its reporting business units beneficially own 4,163,016 shares of Inspire Medical Systems, Inc. common stock, representing 14.4% of the outstanding class as of June 30, 2026.
BlackRock reports sole voting power over 4,116,712 shares and sole dispositive power over all 4,163,016 shares, with no shared voting or dispositive power. The filing notes that iShares Core S&P Small-Cap ETF has an interest in more than five percent of Inspire Medical Systems’ common stock. The disclosure aggregates certain BlackRock business units and excludes others that report ownership separately.
CARREL MICHAEL H reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems, Inc. reported that director Michael H. Carrel received an equity award of 5,631 restricted stock units (RSUs) on July 20, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest in three equal annual installments on the first three anniversaries of the grant date, subject to Carrel’s continued service on the board of directors through each vesting date. Following this award, he is reported as directly holding 5,631 RSUs.
Inspire Medical Systems, Inc. reported that Michael H. Carrel is serving as a director and has submitted an initial Form 3 statement of beneficial ownership. No share holdings, derivative positions, or transactions are reported, and an Exhibit 24 Power of Attorney is referenced.
Inspire Medical Systems, Inc. appointed Michael H. Carrel to its Board of Directors as a Class III director, effective July 20, 2026. His term runs until the company’s 2027 Annual Meeting of Stockholders, and he will also serve on the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee.
Carrel is President, Chief Executive Officer and director of AtriCure, Inc. and has held multiple leadership roles at publicly traded healthcare and technology companies. Under the Non-Employee Director Compensation Policy, he will receive a $55,000 annual cash board retainer, $7,500 annually for each committee, a $300,000 initial restricted stock unit grant vesting over three years, and $200,000 in annual RSU awards following each annual meeting, plus standard director indemnification.
Inspire Medical Systems, Inc. reported that Board member Casey M. Tansey has decided to retire from its Board of Directors and the committees on which he serves, effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting of Stockholders. The company states that his decision is not due to any disagreement regarding operations, policies, or practices.
Tansey has served on the Board for more than eighteen years, representing U.S. Venture Partners and leading Inspire’s Series A financing in November 2007. He has been involved through the company’s founding, initial public offering, and subsequent growth. Inspire expects to announce a new director to replace him in the near future.
Inspire Medical Systems, Inc. director Georgia Melenikiotou reported an acquisition of 344 shares of Common Stock on 2026-07-15. These shares were received at a stated price of $0.0000 per share in lieu of cash fees under the company's Non-Employee Director Compensation Policy, bringing her direct holdings to 8,329 shares.
Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems, Inc. director Casey M. Tansey reported a grant of 346 shares of common stock on July 15, 2026. The shares were received at 0.0000 per share in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this award, Tansey directly holds 26,632 shares and also reports indirect ownership of 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems, Inc. director Gary Lee Ellis received an equity grant of 581 shares of common stock on July 15, 2026, reported as a grant/award acquisition. According to a footnote, these shares were issued in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a stated price of $0.0000 per share. Following this award, Ellis directly holds 11,419 shares of Inspire Medical Systems common stock.
Broader Shelley G reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems, Inc. reported that director Shelley G. Broader received a grant of 383 shares of common stock on 2026-07-15, issued at $0.0000 per share as equity compensation in lieu of cash fees. Following this award, she directly holds 8,854 shares of the company's common stock.
Inspire Medical Systems reports that D. E. Shaw & Co., L.P. (and David E. Shaw) beneficially hold 1,483,107 shares of common stock, representing 5.1% of the class. The filing states shared voting power of 1,374,263 shares and shared dispositive power of 1,483,107 shares. The filing notes that David E. Shaw disclaims beneficial ownership of these shares and that the holders filed jointly.